"In December 2006, Forest Laboratories (FRX) paid $594 million (including $494 million upfront) to acquire Cerexa Inc. The company was just about to enter Phase III trials for ceftaroline, an intravenous cephalosporin antibiotic for use against MRSA and certain gram-negative bacteria. Ceftaroline operates in a somewhat different setting than tedizolid; I consider tedizolid to have more commercial potential. A takeover value of $594 million for Trius translates into $15 per share." That little tidbit is from SmithOnStocks (His articles are a must read, by the way.)
Trius Therapeutics is a big takeover target. There are talks of this by many biotech analysts including this one at Motley Fool. Here he is talking about Cubist Pharmaceuticals (CBST) as a potential buyer. (Here, go to the 3 minute mark)
Trius is an undervalued stock with a market capitalization of around 230 million, with a price per share of 5.21. Potential sales in the United States alone is $400-$450 million. Trius has a commercialization deal with Bayer in the Asia which will provide the company with 100 million dollars in milestones. It will eventually move into Europe.
Based on the above information. I have a price per share target of $13.00 for 2013 and a price per share target of $24.00 for 2014. Although, due to the scarcity of new antibiotics, combined with the superior efficacy results of Tedisolid Phosphate (compared to possibly new antibiotics coming to market), I believe Trius Pharmaceuticals will be a big takeover target by big pharma and will be bought out by the end of 2013.
takeover...not until they release positive phase 3 results...make or break event. CLSN scared the bejessies out of would be hopefuls. Kerx restored some faith. I'm surprised there's no vol.in this space.Yet..